Position in ACLX
as of Mar 31, 2026
· filed May 14, 2026
Position Value
$173,048,436
New position
Shares Held
1,507,128
first reported quarter
Ownership
2.58%
of shares outstanding
% of Portfolio
4.03%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2026
1 quarter on record
Voting authority
Sole 100%
Shared 0%
None 0%
Derivatives in ACLX
reported options exposure · as of Mar 31, 2026CallValue
$0
CallShares
0
PutValue
$510,027
PutShares
4,442
Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.
Position in Biotechnology
Healthcare · as of Mar 31, 2026GLAZER CAPITAL, LLC holds $643,430,833 across 6 Biotechnology names. ACLX ranks #2 (26.9% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | FOLD |
AMICUS THERAPEUTICS, INC.
|
12,722,749 | $183,970,950 | |
| 2 | ACLX |
Arcellx, Inc.
This page
|
1,507,128 | $173,048,436 | |
| 3 | TERN |
Terns Pharmaceuticals, Inc.
|
2,295,498 | $121,018,654 | |
| 4 | DAWN |
Day One Biopharmaceuticals, Inc.
|
4,683,687 | $100,418,249 | |
| 5 | APLS |
Apellis Pharmaceuticals, Inc.
|
1,294,196 | $52,065,505 | |
| 6 | CNTA |
Centessa Pharmaceuticals plc
|
325,001 | $12,909,039 |
All Filings in ACLX
Export CSV
2 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $173,048,436 | 1,507,128 | Shares | Sole | 2026-05-14 | |
| 2026-03-31 | $510,027 | 4,442 | Put | Sole | 2026-05-14 | |
| No filing history on record for this holder in this stock. | ||||||